CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an…
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA…
Earnings call: Heron Therapeutics reports revenue growth in Q1 2024 By Investing.com Earnings call: Heron Therapeutics reports revenue growth in Q1 2024…